Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coya Therapeutics, Inc. (COYA : NSDQ)

• Company Description    Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya Therapeutics Inc. is based in HOUSTON. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $4.25 Daily Weekly Monthly 20 Day Moving Average: 272,959 shares Shares Outstanding: 23.46 (millions) Market Capitalization: $99.69 (millions) Beta: 0.51 52 Week High: $7.75 52 Week Low: $3.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.15% -17.76% 12 Week 0.47% -2.28% Year To Date -26.72% -30.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5850 San Felipe St Suite 500 - HOUSTON,TX 77057 USA ph: 800-587-8170 fax: - ir@coyatherapeutics.com http://www.coyatherapeutics.com

• General Corporate Information    Officers Arun Swaminathan - Chief Executive Officer and Director Howard Berman - Executive Chairman David Snyder - Chief Financial Officer Ann Lee - Director Anabella Villalobos - Director Peer Information Coya Therapeutics, Inc. (CORR.) Coya Therapeutics, Inc. (RSPI) Coya Therapeutics, Inc. (CGXP) Coya Therapeutics, Inc. (BGEN) Coya Therapeutics, Inc. (GTBP) Coya Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22407B108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 23.46 Most Recent Split Date: (:1) Beta: 0.51 Market Capitalization: $99.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.04 Price/Cash Flow: - Price / Sales: 12.56 EPS Growth vs. Year Ago Period: 27.27% vs. Previous Quarter: 5.88% Sales Growth vs. Year Ago Period: -2.71% vs. Previous Quarter: -93.66% ROE 06/30/26 - - 03/31/26 - -55.86 12/31/25 - -62.76 ROA 06/30/26 - - 03/31/26 - -48.86 12/31/25 - -53.84 Current Ratio 06/30/26 - - 03/31/26 - 15.02 12/31/25 - 8.50 Quick Ratio 06/30/26 - - 03/31/26 - 15.02 12/31/25 - 8.50 Operating Margin 06/30/26 - - 03/31/26 - -259.60 12/31/25 - -260.63 Net Margin 06/30/26 - - 03/31/26 - -266.10 12/31/25 - -267.13 Pre-Tax Margin 06/30/26 - - 03/31/26 - -266.07 12/31/25 - -267.09 Book Value 06/30/26 - - 03/31/26 - 2.09 12/31/25 - 2.06 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©